A major step forward has been reached in European healthcare as a key medicines committee has given its backing to AstraZeneca's innovative hypertension pill, known as baxdrostat and to be marketed under the brand name Baxfendy. The Committee for Medicinal Products for Human Use, operating under the European Medicines Agency, recommended the authorization for adult patients whose high blood pressure remains insufficiently controlled despite the use of at least two other traditional medications. Should the final green light be given, Baxfendy is anticipated to become the very first and only aldosterone synthase inhibitor available to patients across the European Union. The novel mechanism of the medication targets and blocks the hormone aldosterone, representing a distinct and innovative approach compared to older blood pressure management treatments currently on the market. This positive regulatory opinion was issued following compelling results gathered from two separate late-stage clinical trials. While the ultimate marketing authorization decision rests with the European Commission, the governing body typically follows the positive recommendations issued by the committee. Internationally, baxdrostat has already secured approvals in the United States and several other countries, while regulatory filings remain actively under review in major markets such as Japan and China. AstraZeneca originally secured the rights to baxdrostat through its substantial 1.8 billion dollar acquisition of CinCor Pharma in 2023, expanding its cardiovascular and metabolic portfolio. Source: Arab News #AstraZeneca #HealthNews #EuropeanUnion #MedicalInnovation #Hypertension
También lo cubren: arabnews.com - Arab News, arabnews.com - Arab News (Arabia Saudí), arabnews.pk - Arab News Pakistan, arabnews.pk - Arab News Pakistan (Arabia Saudí).
Ver más en NewsToday